Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Miller M et al. for the PROVE IT-TIMI 22 Investigators (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724–730

    Article  CAS  Google Scholar 

  2. Schwartz GG et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718

    Article  CAS  Google Scholar 

  3. Cannon CP et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504

    Article  CAS  Google Scholar 

  4. Smith SC Jr et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47: 2130–2139

    Article  Google Scholar 

  5. Grønholdt M et al. (1998) Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation 97: 34–40

    Article  Google Scholar 

  6. Fruchart JC et al. (1999) Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10: 245–257

    Article  CAS  Google Scholar 

  7. Rosenson RS (2003) Lipid-lowering drugs and rheology. In Lipids and Atherosclerosis Annual 2003. 19–35 (Eds Gaw A and Shepherd J) London: Martin Dunitz

    Google Scholar 

  8. Cromwell WC and Otvos JD (2006) Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 98: 1599–1602

    Article  CAS  Google Scholar 

  9. Brunzell JD et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512–1524

    Article  Google Scholar 

  10. Otvos JD et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veteran Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556–1563

    Article  CAS  Google Scholar 

  11. Otvos JD et al. (2002) Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 trial. Atherosclerosis 160: 41–48

    Article  CAS  Google Scholar 

  12. Bakker-Arkema RG et al. (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128–133

    Article  CAS  Google Scholar 

  13. Hunninghake DB (2001) Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. Am J Cardiol 88 (Suppl): 37K–41K

    Article  CAS  Google Scholar 

  14. Rosenson RS et al. (2007) Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30: 1945–1951

    Article  CAS  Google Scholar 

  15. Rosenson RS (2007) Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol 99 (Suppl): 96B–104B

    Article  CAS  Google Scholar 

  16. Crisby M et al. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926–933

    Article  CAS  Google Scholar 

  17. Rosenson RS 2008 Fenofibrate treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 6: 1319–1330

    Article  CAS  Google Scholar 

  18. Rosenson RS et al. (2008) Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 198: 381–388

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert S Rosenson.

Ethics declarations

Competing interests

RS Rosenson has received speakers' bureau honoraria and research support and has acted as a consultant for Abbott and AstraZeneca. Dr Rosenson has also received speakers' bureau honoraria from Solvay. B Pitt declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R., Pitt, B. Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nat Rev Cardiol 6, 98–100 (2009). https://doi.org/10.1038/ncpcardio1435

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1435

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing